Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase II trial of RM-493 for treatment of obesity begins

Jan. 7, 2013

Arena Pharmaceuticals prepares new GPR119 receptor ligands

Jan. 7, 2013

Novel candidate antidiabetic drugs patented by Ajinomoto

Jan. 7, 2013

Alnylam files application for phase I study of RNAi therapeutic in the U.K.

Jan. 4, 2013

NGM signs agreement with Janssen for novel therapeutics for diabetes

Jan. 4, 2013

Updated results presented from the GAUSS trial of AMG-145

Jan. 4, 2013

Novel DGAT1 inhibitors synthesized at Daiichi Sankyo

Jan. 4, 2013

Receptos patents new GLP-1 receptor modulators

Jan. 4, 2013

Alize Pharma launches collaborative research program for AZP-531

Jan. 4, 2013

FDA deems complete Merck & Co's resubmission of NDA for ezetimibe/atorvastatin tablets

Jan. 3, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...